ZNF573 Inhibitors
Chemical inhibitors of ZNF573 target various cellular pathways to achieve functional inhibition of the protein. Paclitaxel, a microtubule stabilizer, can inhibit ZNF573 by hampering the normal microtubule dynamics essential for the protein's cellular distribution and function. Similarly, inhibitors of key signaling pathways such as Rapamycin, Wortmannin, and LY294002 can inhibit ZNF573 through their action on the mTOR and PI3K/AKT pathways, respectively. These pathways are often crucial for a multitude of cellular processes including those that could govern the function or stability of ZNF573. By reducing the activity within these pathways, these inhibitors can diminish the functional capacity of ZNF573.
Furthermore, U0126 and SB203580, which target MEK1/2 and p38 MAP kinase respectively, can inhibit ZNF573 by disrupting signaling cascades that could be necessary for ZNF573's activity. U0126 prevents the activation of ERK1/2, potentially inhibiting ZNF573's role in related cellular responses, while SB203580 could affect downstream targets involved in ZNF573-regulated processes. The JNK inhibitor SP600125 can inhibit ZNF573 by modifying the activity of transcription factors and regulatory proteins that may interact with ZNF573. Proteasome inhibitors like Bortezomib and MG132 can lead to an accumulation of proteins within the cell, indirectly inhibiting ZNF573 by interfering with protein homeostasis. Alsterpaullone and Roscovitine, both CDK inhibitors, can inhibit ZNF573 by disrupting cell cycle-related processes and the phosphorylation status of proteins involved in ZNF573 regulation. Finally, ZM447439, an Aurora kinase inhibitor, can inhibit ZNF573 by impairing cell division and chromosomal segregation processes, potentially involving ZNF573 and affecting its contribution to these critical cellular events.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Paclitaxel stabilizes microtubules and prevents their disassembly, which can inhibit ZNF573 by disrupting the microtubule dynamics required for its localization or trafficking within the cell, thus impeding its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a kinase involved in cell growth and protein synthesis. By inhibiting mTOR, Rapamycin can reduce the cellular resources necessary for the function of ZNF573, leading to its functional inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an inhibitor of PI3K, which indirectly can inhibit ZNF573 by disrupting PI3K/AKT signaling pathway that might be crucial for ZNF573's function or stability. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, another PI3K inhibitor, can inhibit ZNF573 by blocking the PI3K/AKT pathway, potentially affecting the phosphorylation state and activity of proteins that interact with or regulate ZNF573. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, which could lead to the inhibition of ZNF573 by preventing the activation of ERK1/2, a pathway that may be required for the proper function of ZNF573. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAP kinase, potentially leading to the inhibition of ZNF573 by affecting downstream signaling pathways that regulate cellular responses wherein ZNF573 is functionally involved. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 inhibits JNK, which could inhibit ZNF573 by altering the activity of transcription factors and co-regulators that may interact with or control the function of ZNF573. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits the 26S proteasome, which could lead to the accumulation of misfolded or damaged proteins, indirectly affecting the function of ZNF573 by perturbing the protein homeostasis that it relies on. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 also inhibits the proteasome and can inhibit ZNF573 by causing an accumulation of proteins that may sequester ZNF573 or otherwise impede its normal function through altered protein interactions or degradation pathways. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases (CDKs), and can inhibit ZNF573 by disrupting cell cycle progression and the potential involvement of ZNF573 in cell cycle-regulated processes. | ||||||